Navigation Links
In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine"

Nisola LLC launches campaign for stricter regulatory approval requirements and continuity of product supply.

New York, NY (PRWEB) May 27, 2009 -- A recent report released by Wolters Kluwer Health predicts that by the end of the year, nearly two-thirds of all drug prescriptions will be filled with generic drugs. This march to generics is fueled by several factors, which include the current economy, ever-increasing co-payment requirements for brand name drugs and pharmacies' desire to increase their profits by filling prescriptions with high margin generics versus lower margin brand name medicines.

This reliance on generics is generally considered a positive shift in healthcare as the vast majority of patients see significant cost savings without any noticeable change in their treatment. However, in the case of many neurological disorders, especially epilepsy, switching from a brand to a generic or between generics can be extremely dangerous.

The primary problem with random product substitution is that the Food and Drug Administration (FDA) does not require generic drugs to definitively demonstrate therapeutic equivalence to their brand name counterparts (i.e., the same clinical efficacy and safety profile). In fact, for approval, the FDA only requires that the generic be bioequivalent (i.e., within a certain range of a brand name drug's potency as measured by single-dose blood tests in healthy volunteers). Additionally, pharmacies, in their quest for profits, not only push patients to switch from brand name drugs to generics, but often switch from one generic manufacturer to another. Most alarmingly from an epilepsy patient's perspective, this means that one can receive a different generic brand every time they refill their prescriptions. This is understandably a nightmare for a patient trying to regulate their medications to avoid both seizures and/or side effects.

"Generic drugs can vary between 80% and 125% of the potency of the original brand they're modeled on," explains Eric Liebler, CEO of Nisola LLC, a neurological advocacy and business strategy consulting firm. "While that may not be an issue for a person using generic Vicodin to occasionally treat an achy back, for a patient with life-long epilepsy, that 45% variance can mean the difference between a normal, seizure-free life and dealing with the risk of breakthrough seizures, brain damage and even death."

Urging the healthcare community to strive for "Good Medicine," Liebler, a longtime supporter of best practices in the treatment of neurological diseases, announced today that Nisola is calling for a coordinated awareness campaign to educate patients, healthcare professionals and policymakers about the risks involved when switching from branded Anti-Epileptic Drugs (AEDs) to generics. Furthermore, the campaign aims for strengthened regulations and practices, to ensure that patients receive consistently safe and effective AEDs throughout the course of their treatment.

Nisola's "Good Medicine" campaign seeks:

1.   Extensive & Appropriate Clinical Testing - The FDA should reconsider its generic approval protocol with regard to generic AEDs so that they are proven to be therapeutically equivalent, not just bioequivalent, to the innovator drug.

"For the treatment of many neurological diseases and epilepsy in particular, the FDA should make the generic manufacturers prove their products are safe and effective rather than placing the burden on doctors and patients to prove that they aren't safe," said Liebler.

2.   Prudence & Patience - Before approving any more generic AEDs, Liebler suggests that the FDA wait on a study currently being planned by the National Institute for Neurological Disorders and Stroke (NINDS), which will examine the issue of therapeutic equivalence versus bioequivalence as well as the potential dangers when switching from a brand name to a generic or being subject to the random substitution of one generic for another. The study is expected to begin shortly, and when it is completed it will enable the FDA to apply the most definitive data to its generic approval process for AEDs.

"The FDA has acknowledged that current studies gauging the therapeutic equivalence of many generic AEDs are inconclusive. These studies show that certain drugs are chemically similar to the original brand, but do not prove that they are effective. It is risky for the FDA to approve generic drugs without complete data, so it makes sense that they wait for conclusive information to become available. Given the pending NINDS research project, the good news is that they won't have to wait long," said Liebler.

3.   Continuity - To make certain that epilepsy patients receive the economic benefits of generic pharmaceuticals, pharmacies, insurance companies and health service providers must work together to create a system - similar to that in Europe - whereby they guarantee that the patient will receive the same generic medication throughout the course of their treatment.

"We can save the patient money and protect their health by always providing them with the same generic medication, month after month," said Liebler.

Nisola's "Good Medicine" campaign, though in support of stricter regulations, is not against the development of generic AEDs. Nisola supports drugs that are affordable and, more importantly, safe for everyone. However, Liebler notes, "Until we can be certain that generic medications are proven as safe and effective as the originator brand, or that pharmacies can ensure the drug's continuity, patients should stick to the drug in which they have confidence. No cost is too great when it comes to your health."

Nisola's "Good Medicine" campaign goals to improve the testing protocols used to approve generic AEDs and to eliminate the random switching of generics are shared by the Epilepsy Foundation, American Epilepsy Society and the American Academy of Neurology (AAN). The Epilepsy Foundation, which just recently launched its own campaign to raise awareness of these issues, has more than 1,000 stories to share about the needless suffering of people with epilepsy due to current testing and regulatory policies. Says Liebler: "If we don't improve this situation immediately there could, unfortunately, be thousands more stories to tell."

Recently honored at AAN's annual meeting with the AAN Foundation's prestigious Chair's Award, Liebler has positioned himself and Nisola as advocates for "Good Medicine" in the field of neurology. His 20-plus years of experience in the neurological community have provided him with exceptional insight on the important needs of the professionals and consumers who are concerned with the health and safety of epilepsy patients.

Epilepsy is a chronic neurological disorder affecting nearly three million Americans. Each year, approximately 200,000 people in the U.S. are diagnosed with epilepsy. Although initial onset can occur at any age, epilepsy most commonly arises in either early childhood or old age.

Nisola LLC ( is an advocacy and business strategy consulting firm that is focused on serving clients interested or involved in the field of neurology. The company's core area of strength is its experience and understanding of the interplay between science, clinical medicine, product development and commercialization. Nisola works closely with clients to accelerate and enhance their ability to understand and interact with the relevant medical and patient constituencies. For more information on epilepsy or how you can help the campaign for "Good Medicine," please contact Nisola at (908) 437-1320 or by email at eliebler(at)


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Mutant gene causes epilepsy, intellectual disability in women
2. Novel Techniques Offers New Freedom to Patients with Parkinson's Disease, Epilepsy, Dystonia, and Tremor
3. Guidelines: Pregnancy Safe with Epilepsy, but Valproate Should be Avoided
4. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
5. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
9. Generic prostate drug helps find high-risk cancers early
10. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory
11. Mylan Vice Chairman and CEO Robert J. Coury to Ring NYSE Closing Bell(R) in Celebration of Merck Generics Acquisition
Post Your Comments:
(Date:1/13/2017)... Madrid, Spain (PRWEB) , ... January 13, 2017 , ... ... the Melia Avenida America hotel on March 3-4, 2017. This Congress is expertly ... focused on the management of patients with lung cancer. , Chaired by Dr. Giorgio ...
(Date:1/13/2017)... ... 13, 2017 , ... KOAMTAC ®, Inc., a leading manufacturer of Bluetooth ... companion scanner and data collector at the National Retail Federation’s Big Show (NRF17) held ... answer to the market’s need for more compact and rugged devices for collecting barcode ...
(Date:1/13/2017)... (PRWEB) , ... January 13, 2017 , ... An inventor from Pahrump, Nev., used an ... "My urologist had me wear a Foley catheter and urine bag for a half year ... uncomfortable, so I decided that there should be a better way to do this." , ...
(Date:1/13/2017)... ... January 13, 2017 , ... People who have sensitive teeth are ... whenever they brush their teeth. Sadly, most dental hygiene products in the market contain ... teeth. For these people, continuing their daily oral care routine to keep their teeth ...
(Date:1/13/2017)... , ... January 13, 2017 , ... Friday, January 13 ... of the game room, increasing the size of the location to 90,000 square feet. ... 8-hole mini golf course that takes customers on an educational tour of the historic ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... , January 13, 2017 ... "Transfection Reagents and Equipment Market by Method (Biochemical ... Application (Biomedical, Protein Production), End User - Global ... studies the global market from 2016 to 2021. ... Billion by 2021 from USD 715.4 Million in ...
(Date:1/13/2017)... 2017 The 2016 election resulted in ... states voting in favor of legalizing cannabis for recreational use, ... in the U.S. In addition, the state of ... cannabis products sales. The ArcView Group has published an updated ... cannabis sales in the U.S. last year reached $6.7 billion, a ...
(Date:1/13/2017)... Jan. 12, 2017  Rosen Law Firm, a global ... class action lawsuit on behalf of purchasers of Alexion ... February 10, 2014 through November 9, 2016, inclusive (the ... Alexion investors under the federal securities laws. ... or call Phillip Kim, Esq. ...
Breaking Medicine Technology: